Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 3521 in Advanced Melanoma and NSCLC
NCT00003989Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 1998
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 9
01
Overview
A Phase 2 trial of aprinocarsen in melanoma, non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jun 1998; status: completed.
02
Drugs
aprinocarsen
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003989.